Hepatitis A antibodies in attenders of London Travel Clinics: cost-benefit of screening prior to hepatitis A immunisation.
The seroprevalence of hepatitis A antibodies in travellers attending London Travel Clinics increases with age and screening may eliminate the need for vaccination at present for approximately 40% of adults. The duration of protection by current hepatitis A vaccine(s) is still to be established.
Zuckerman
J N
JN
Occupational Health Unit, Royal Free Hospital School of Medicine, London, England.
Powell
L
L
D000328:Adult; D000367:Age Factors; D000368:Aged; D003362:Cost-Benefit Analysis; D003430:Cross-Sectional Studies; D005260:Female; D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D017957:Hepatitis A Virus, Human / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis*; D006801:Humans; D008131:London / Q000453:epidemiology; D008297:Male; D008403:Mass Screening; D008875:Middle Aged; D016036:Seroepidemiologic Studies; D014611:Vaccination / Q000191:economics; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000191:economics
D035922:Hepatitis A Antibodies; D022362:Hepatitis A Vaccines; D006508:Hepatitis Antibodies; D014761:Viral Hepatitis Vaccines